C-Glycoside analogues of β-galactosylceramide with a simple ceramide substitute: Synthesis and binding to HIV-1 gp120

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 4, 2006, Pages 1182-1188

  Augustin, Line A ^a   Fantini, Jacques ^b   Mootoo, David R ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Aza C glycoside gp120; C Glycoside; Galactosyl ceramide; Oxocarbenium ion

Indexed keywords

1,5 ANHYDRO 1 C HEPTADECYL DEXTRO GALACTITOL; 1,5 DIDEOXY 1 C HEPTADECYL 1,5 IMINO DEXTRO GALACTITOL; BETA GALACTOSIDE; CARBOHYDRATE; GALACTOSYLCERAMIDE; GLYCOLIPID; GLYCOPROTEIN GP 120; GLYCOSIDE; STEARIC ACID; THIOACETALDEHYDE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; SUBSTITUTION REACTION;

GALACTOSYLCERAMIDES; GLYCOSIDES; HIV ENVELOPE PROTEIN GP120; HIV-1; MOLECULAR STRUCTURE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 30344434993     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2005.09.044     Document Type: Article

References (37)

1. J.M. Harouse, S. Bhat, S.L. Spitalnik, M. Laughlin, K. Stefano, D.H. Silberberg, and F. Gonzalez-Scarano Science 252 1991 320 323
2. J. Fantini, D.G. Cook, N. Nathanson, S.L. Spitalnik, and F. Gonzalez-Scarano Proc. Natl. Acad. Sci. U.S.A. 90 1993 2700 2704
3. G. Fotopoulos, A. Harari, P. Michetti, D. Trono, G. Pantaleo, and J.-P. Kraehenbuhi Proc. Natl. Acad. Sci. U.S.A. 99 2002 9410 9414
4. For a discussion of inherent limitations with different assays: J.C. Conboy, K.D. McReynolds, J. Gervay-Hague, and S.S. Saavedra J. Am. Chem. Soc. 124 2002 968 977
5. S. Bhat, S.L. Spitalnik, F. Gonzalez-Scarano, and D.H. Silberberg Proc. Natl. Acad. Sci. U.S.A. 88 1991 7131 7134
6. D. Long, J.F. Berson, D.G. Cook, and R.W. Doms J. Virol. 68 1994 5890 5898
7. T. McAlarney, S. Apostolski, S. Lederman, and N. Latov J. Neurosci. Res. 37 1994 453 460
8. D. Hammache, G. Piéroni, N. Yahi, O. Delézay, N. Koch, H. Lafont, C. Tamalet, and J. Fantini J. Biol. Chem. 273 1998 7967 7971
9. K.D. McReynolds, M.J. Hadd, and J. Gervay-Hague Bioconjugate Chem. 10 1999 1021 1031
10. K.D. McReynolds, A. Bhat, J.C. Conboy, S.S. Saavedra, and J. Gervay-Hague Biorg. Med. Chem. 10 2002 625 637
11. C.R. Bertozzi, D.G. Cook, W.R. Kobertz, F. Gonzalez-Scarano, and M.D. Bednarski J. Am. Chem. Soc. 114 1992 10639 10641
12. J. Fantini, D. Hammache, O. Delézay, N. Yahi, C. André-Barrès, I. Rico-Lattes, and A. Lattes J. Biol. Chem. 272 1997 7245 7252
13. I. Rico-Lattes, M.-F. Gouzy, André-Barrès, B. Guidetti, and A. Lattes New J. Chem. 6 1998 451 457
14. R. Villard, D. Hammache, G. Delapierre, F. Fotiadu, G. Buono, and J. Fantini ChemBioChem 3 2002 517 525
15. D. Hammache, N. Yahi, M. Maresca, G. Pieroni, and J. Fantini J. Virol. 73 1999 5244 5248
16. K.T. Weber, D. Hammache, J. Fantini, and B. Ganem Bioorg. Med. Chem. Lett. 10 2000 1011 1014
17. For seminal work on C-glycoside analogues of GalCer, see Ref. 10. Other examples of C-glycolipids: G. Yang, R.W. Franck, R. Bittman, P. Samadder, and G. Arthur Org. Lett. 3 2001 197 200
18. G. Yang, R.W. Franck, H.-S. Byun, R. Bittman, P. Samadder, and G. Arthur Org. Lett. 1 1999 2149 2151
19. G. Yang, J. Schmieg, M. Tsuji, and R.W. Franck Angew. Chem. Int. Ed. Engl. 43 2004 3818 3822
20. A. Dondoni, D. Perrone, and E. Turturici J. Org. Chem. 64 1999 5557 5564
21. L. Cipolla, F. Nicotra, E. Vismara, and M. Guerrini Tetrahedron 53 1997 6163 6170
22. N. Khan, X. Cheng, and D.R. Mootoo J. Am. Chem. Soc. 121 1999 4918 4919
23. X. Cheng, G. Kumaran, and D.R. Mootoo Chem. Commun. 2001 811 812
24. Alcohol 7 is available in five steps from commercially available d-lyxose in an overall yield of approximately 60%. N. Khan, X. Cheng, and D.R. Mootoo J. Org. Chem. 65 2000 2544 2547
25. For related examples of stereoselective hydroboration of Cl-substituted galactals: D. Calimente, and M.H.D. Postema J. Org. Chem. 64 1999 1770 1771
26. R.R. Schmidt, and H. Dietrich Liebigs. Ann. Chem. 1994 975 981
27. P.L. Barili, G. Catelani, F. D'Andrea, and E. Mastrorilli J. Carbohydr. Chem. 16 1997 1001 1010
28. R.V. Stevens Acc. Chem. Res. 17 1984 289 296
29. E.W. Baxter, and A.B. Reitz J. Org. Chem. 59 1994 3175 3185
30. O.R. Martin, and O.M. Saavedra J. Org. Chem. 61 1996 6987 6993
31. R. Mahfoud, R. Mylvaganam, C.A. Lingwood, and J. Fantini J. Lipid Res. 43 2002 1670
32. M.S. Briggs, L.M. Gierasch, A. Zlotnick, J.D. Lear, and W.F. DeGrado Science 228 1985 1096 1099
33. A.M. Batenburg, R.A. Demel, A.J. Verkleijg, and B. de Kruijff Biochemistry 27 1988 5678 5685
34. R.D. Kensinger, B.J. Catalone, F.C. Krebs, B. Wigdahl, and C. Schengrund Antimicrob. Agents Chemother. 2004 1614 1623
35. An aromatic Phe residue in the V3 loop of HIV-1 gp120 is directly involved in GalCer binding, so that the aromatic phenyl cycle stacks onto the sugar cycle. N. Taieb, N. Yahi, and J. Fantini Adv. Drug Deliv. Rev. 56 2004 779 794 An interesting speculation is that the protonated azasugar analogue could engage in a favorable NH-π interaction with the aromatic ring, leading to increased binding of 4 to gp120 (relative to 1 and 3). Alternatively, it is conceivable that the electrostatic repulsion between the protonated amine in adjacent molecules of 4 could reduce the overall lipid-lipid attraction in monolayers formed from 4 relative to monolayers from the neutral analogues 1 and 3. This effect could lead to a monolayer of 4 that is intrinsically more 'penetrable' (i.e., with a greater critical pressure of insertion)
36. A. Karpas, G.W. Fleet, R.A. Dwek, S. Petursson, S.K. Namgoong, N.G. Ramsden, G.S. Jacob, and T.W. Rademacher Proc. Natl. Acad. Sci. U.S.A. 85 1988 9229
37. G.B. Karlsson, T.B. Butters, R.A. Dwek, and F.M. Platt J. Biol. Chem. 268 1993 570